natgillin/translations-raw huggingface dataset:
A method for receiving digital video broadcasting data in a receiver, the method comprising: receiving a broadcast signal comprising a signal frame, wherein the signal frame comprises preamble symbols including constellation values corresponding to Layer 1 signaling data, referred to as L1 signaling data, and a Layer 1 header and data symbols including at least one data slice that comprises Physical Layer Pipe data, wherein the preamble symbols are divided into Layer 1 blocks and each Layer 1 block has 3408 subcarriers, and wherein the Layer 1 header includes Layer 1 Time Interleaving mode information, referred to as L1 mode information, that indicates a time interleaving depth and L1_INFO_SIZE information that indicates the half size of the L1 signaling data and Layer 1 block padding data; 
Prijamnik iz bilo kojeg od patentnih zahtjeva 9 do 11, pri čemu postupci raspletanja bitova i vremena nisu izvedeni narazini 1. Metoda za obradu emitiranog podatka u prijamniku, metoda obuhvaća: prihvaćanje emitiranog signala koji obuhvaća okvir signala, pri čemu okvir signala obuhvaća simbole početnog niza uključujući konstelacijske vrijednosti koje odgovaraju signalnom podatku razine 1, naznačenom kao signalni podatak L1, 1 zaglavlje razine 1, pri čemu su simboli početnog niza razine 1 podijeljeni u blokove i svaki blok razine 1 ima 3408 podnosača, i pri čemu zaglavlje razine1l uključuje informaciju vrste umetanja vremena razine 1,
binds to human PD-1 with a kdissoc of about 2.7 x 10-5 l/s or slower; binds to human PD-1 with a kdissoc of about 3 x 10-5 l/s or slower; or blocks binding of human PD-L1 and/or human PD-L2 to human PD-1 with an IC50 of about 1 nM or lower. 
V/s ili sporije; veže se za humani PD-1 sa kggC od oko 2.7 x 10? 1/s ili sporije; veže se za humani PD-1 sa kaieoC od oko 3 x 10% Vs ili sporije; ili blokira vezanje humanog PD-L1 i/ili humanog PD-L2 za humani PD-1 sa ICso od oko 1 nM ili niže.
The immunogenic composition of claim 9, which further comprises at least one active immunogenic component derived from a pathogen other than paramyxovirus. 
Multivalentna imunogena smjesa prema patentnom zahtjevu 12, gdje je najmanje jedna aktivna imunogena komponenta
The method of claim 9, wherein the excipient is a preservative, such as benzyl alcohol. 
Pripravak u skladu s patentnim zahtjevom 5, naznačen time što je navedena pomoćna tvar konzervans, poput benzil-alkohola.
Process for producing a setting accelerator for a dry mortar blend, the setting accelerator in the form of a powder comprising calcium nitrate, wherein the process comprises the step of processing prills and/or granules comprising calcium nitrate and at least a different nitrate salt forming the setting accelerator having a water content higher than 5% and lower than 20% and a particle size of 0.1 mm to 1 mm. 
Postupak za proizvodnju akceleratora vezivanja za smjesu suhog morta, akcelerator vezivanja je u obliku praha koji sadržava kalcijev nitrat, naznačen time, da postupak obuhvaća korak prerade zrnaca i/ili granula koje sadržavaju kalcijev nitrat i barem jednu drugačiju nitratnu sol da bi se dobio akcelerator vezivanja koji ima udjel vode veći od 5 % i manji od 20 % 1 veličinu čestica od 0,1 mm do 1 mm.
The production method according to any one of claims 19 to 21, wherein the compound represented by the formula [11b] is isolated in the form of a solid. 
Metoda prema patentnom zahtjevu 13, gdje spoj predstavljen formulom [11b] je izoliran u obliku čvrste supstance.
The invention also relates to a method for producing an isotopic mixture of cholesterol, of cholesterol intermediates or of cholesterol metabolites, labeled at various positions using isotope labels, comprising culturing an organism of the kingdom Fungi as defined above on a labeled substrate and then on an unlabeled substrate, the culture times on each of these substrates being chosen in order to obtain a defined isotope profile. 
Postupak dobivanja izotopne smjese kolesterola, ili međuprodukata ili metabolita kolesterola, obilježenih na različitim položajima uz pomoć izotopnih biljega, naznačen time što se sastoji u stavljanjem organizma u skladu s bilo kojim od patentnih zahtjeva 1 do 7 u kulturu na obilježenom supstratu, a zatim na neobilježenom supstratu, gdje je broj uzgajanja na svakom od tih supstrata tako odabran da se postigne definirani izotopni profil.
The objectives and other advantages of the invention may be realized and attained by the structure particularly pointed out in the written description and claims hereof as well as the appended drawings. To achieve the objects, the present invention provides a method of transmitting a signal, includes generating a second pilot signal including a layer-1 information region for assigning layer-1 information, arranging the generated second pilot signal in a preamble of a signal frame, and arranging a physical layer pipe (PLP) in a specific region of the layer-1 information region, and modulating the signal frame and transmitting the signal frame via at least one radio frequency (RF) channel. 
Postupak prijenosa emitiranja okvira signala digitalne televizije, DTV, naznačen time, što se sastoji od: generiranja ($531) sloja-1 informacije, sloj-L informacije je fizički parametar za signalizaciju voda na fizičkom sloju, PLP, isporukom servisnog toka; izgradnje (S533) okvira signala koji se sastoji od korisnih sadržaja i uvoda, uvod obuhvaća prvi pilot signal koji prethodi drugom pilot signalu, drugi pilot signal uključuje sloj-!1 informacije u čemu PLP je uključen u korisne sadržaje i drugi pilot signal, i prijenosa okvira signala putem najmanje jedne radio frekvencije, RF, kanala.
A method of treatment of psychotic disorders which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in any of claims 1 to 29 or a pharmaceutically acceptable salt thereof. 
Upotreba spoja, ili njegove farmaceutski prihvatljive soli, u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačena time što je navedeni spoj namijenjen proizvodnji medikamenta za liječenje psihotičnih poremećaja.
The gown according to claim 12 wherein the first cord and the second cord are temporarily attached at the top portion of the gown utilizing a loop for the temporary secured attachment located in the shoulder area of the left and right side portions of the back portion of the gown. A gown comprising: 
Kuta prema zahtjevu 4, naznačena time, da svaka vrpca privremeno pričvršćena sa dva mjesta na gornjem dijelu kute i to uz primjenu principa kopče i karike za privremeno pričvršćivanje, položeno u području ramena lijevog i desnog postranog dijela (3, 4) leđnog dijela kute.
The method according to claim 1 wherein said at least cabodiimide is N, N'-Dicyclohexylcarbodiimide (DDC), or 1 - ethyl-3-(3-dimethyl aminopropyl) carbodiimide (EDC), such as in its hydrochloride form. 
Metoda u skladu sa patentnim zahtjevom 1 gdje navedeni najmanje kabodiimid je N, N'-Dicikloheksilkarbodiimid (DDC), ili 1 - etil-3-(3-dimetil aminopropil) karbodiimid (EDC), kao što je u njegovom hidroklorid obliku.
Number of events 
Broj međunarodne prijave:
An oral formulation according to claim 9 wherein the ocular neovascular disorder is exudative age-related macular degeneration (AMD). 
Topikalna formulacija namijenjena za upotrebu u skladu s patentnim zahtjevom 10, naznačena time što neovaskularni poremećaj oka je eksudativna staračka degeneracija makule (AMD).
Preferably, the first colon cleansing solution comprises polyethylene glycol (PEG). 
Komplet prema zahtjevu 15 naznačen time da prva otopina za čišćenje debelog crijeva sadrži:
The deprotection according to method 12 can be performed as described in method 9. 
Deprotekcija u skladu s metodom 12 može se provesti kako je to opisano u metodi 9.
The improved fodder-dispensing device, according to claim 12, characterised in that the lateral securing means of the bales (4) comprise at least one inclined lateral rod (18) that emerges from the at least one tilting platform (11, 12). 
Poboljšani uređaj za raspodjelu stočne hrane, u skladu sa zahtjevom 12, naznačen je time da bočna sredstva za osiguranje bala (4) obuhvaćaju barem jednu kosu bočnu šipku (18) koja izlazi iz barem jedne nagibne platforme
wherein the Fc domain comprises a modified CH2 domain comprising at least one substitution, optionally wherein the substitution is selected from the group consisting ofP238S, P331S, N297S or a combination thereof. 
(b) pri čemu Fc domena sadrži modificiranu CH2 domenu koja sadrži barem jednu supstituciju, proizvoljno pri čemu je supstitucija odabrana iz skupine koju čine P238S, P331S, N297S ili njihova kombinacija.
In one aspect, the present invention provides a fumarate salt of compound (I) wherein the molar ratio between compound (I) and fumaric acid is 1:1. 
Fumarat sol spoja (I) je predstavljena slijedećom strukturnom formulom: pri čemu je molarni odnos između spoja (1) i fumarne kiseline 1:1.
Accordingly, it is desirable to use a 2′-hydroxyl protecting group that can be removed under less harsh conditions, such as a TES protecting group. 
Prema tome, poželjno je da se koristi 2'-hidroksil zaštitna skupina koja može biti uklonjena pod manje HR P20080057 T3 nepovoljnim uvjetima, kao što je TES zaštitna skupina.
annealing the first complementary sequence of the joiner oligo to the first digested nucleic acid and the second complementary sequence of the joiner oligo to the second nucleic acid; and 
sparivanje prve komplementarne sekvence spojnog oligonukleotida sa prvom digestiranom nukleinskom kiselinom i druge komplementarne sekvence spojnog oligonukleotida sa drugom nukleinskom kiselinom; i
leukotriene antagonists, such as montelukast and zafirulast, for the treatment of allergic rhinitis, COPD, allergic dermatitis, allergic conjunctivitis, etc—please specifically refer to the claims in WO 01/78697 A2; 
Upotreba u skladu s patentnim zahtjevom 7, naznačena time što je alergijska bolest bronhijalna astma, alergijski rinitis, alergijski dermatitis, alergijski konjunktivitis ili alergija na hranu.
an energy store comprising at least one battery cell, and 
bateriju (16) koja ima najmanje jednu ćeliju baterije (55) i
Accordingly, the present invention provides a bifunctional molecule comprising a polypeptide binding partner specific for a given pMHC epitope, and an immune effector polypeptide, the N-terminus of the pMHC binding partner being linked to the C-terminus of the immune effector polypeptide, PROVIDED THAT the said polypeptide binding partner is not a T-cell receptor comprising the alpha chain SEQ ID No: 7 and the beta chain SEQ ID No: 9. As mentioned, the polypeptide pMHC binding partner may be an antibody or a TCR. Thus in one embodiment of the invention the pMHC binding partner is a heterodimeric TCR polypeptide pair, or a single chain TCR polypeptide, and the N-terminus of the a or B chain of the heterodimeric TCR polypeptide pair, or the N-terminus of the scTCR polypeptide, is linked to a C-terminal amino acid of the immune effector polypeptide. 
Bifunkcionalna molekula koja sadrži polipeptidni vezivajući partner specifičan za navedeni pMHC epitop, i imuni efektorni polipeptid, pri čemu je N-terminus pMHC vezivajućeg partnera vezan za C-terminus imunog efektornog polipeptida, UZ UVJET DA navedeni polipeptidni vezivajući partner nije T-stanični receptor koji sadrži alfa lanac SEQ ID No: 7 i beta lanac SEQ ID No: 9, pri čemu pMHC vezivajući partner je heterodimerni aB TCR polipeptidni par, ili jednolančani af TCR polipeptid, i N-terminus o. ili B lanca heterodimernog TCR polipeptidnog para ili Nterminus sc TCR polipeptida, je vezan sa C-terminalnom aminokiselinom imunog efektornog polipeptida i pri čemu imuni efektorni polipeptid je antitijelo koje se specifično veže za antigen predstavljen preko T-stanice.
Aerosol compositions suitable for inhalation can be either a suspension or a solution and generally contain the active ingredient (s) and a suitable propellant such as a fluorocarbon or hydrogencontaining chlorofluorocarbon or mixtures thereof, particularly hydrofluoroalkanes, e. g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetra-fluoroethane, especially 1,1, 1, 2-tetrafluoroethane, 1,1, 1,2, 3,3, 3-heptafluoro-n-propane or a mixture thereof. 
Pripravci u obliku aerosola prikladni za inhalaciju mogu biti suspenzije ili otopine, a općenito sadrže djelatni sastojak (sastojke) i prikladno potisno sredstvo, primjerice fluorougljike ili klorofluorougljike koji sadrže vodik ili njihove smjesa, osobito hidrofluoroalkane, npr. diklorodifluorometan, triklorofluoromctan, diklorotetrafluoroctan, osobito 1,1,1,2-tetrafluoroctan, 1,1,1,2,3,3,3-heptafluoro-n-propan ili njihove smjese.
The composition according to claim 1, which composition is a tablet comprising the compound 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine and pharmaceutically acceptable acid addition salts thereof, mannitiol, microcrystalline cellulose, sodium starch glycolate, hydroxypropyl cellulose and magnesium stearate, which tablet is coated with methacrylic acid ethyl acrylate (1:1) copolymer. 
Sastav u skladu s patentnim zahtjevom 1, gdje je sastav tableta koja sadrži tvar 1-[2-(2,4-dimetil-fenilsulfanil)- fenillpiperazin i njegove farmaceutski prihvatljive soli kiselinskog dodatka, manitol, mikrokristaliničnu celulozu, natrijev škrobni glikolat, hidroksipropilcelulozu i magnezijev stearat, gdje je tableta obložena metakrilnom kiselinom etil akrilatom (1:1) kopolimerom.
A product comprising a compound as claimed in any one of claims 1 to 12 and one or more of the agents listed in claim 20 as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of allergic asthma, perennial allergic rhinitis, seasonal allergic rhinitis, atopic dermatitis, contact hypersensitivity (including contact dermatitis), conjunctivitis, especially allergic conjunctivitis, eosinophilic bronchitis, food allergies, eosinophilic gastroenteritis, inflammatory bowel disease, ulcerative colitis and Crohn's disease, mastocytosis, autoimmune diseases such as hyper IgE syndrome and systemic lupus erythematus, psoriasis, acne, multiple sclerosis, allograft rejection, reperfusion injury, chronic obstructive pulmonary disease, rheumatoid arthritis, psoriatic arthritis and osteoarthritis. 
Proizvod koji sadrži spoj prema bilo kojem od zahtjeva 1 do 12 i jedan ili više agensa navedenih u zahtjevu 20 kao kombinirani pripravak za istovremenu, odvojenu ili uzastopnu upotrebu u liječenju ili prevenciji alergijske astme, perenijalnog alergijskog rinitisa, sezonskog alergijskog rinitisa, atopičnog dermatitisa, kontaktne preosjetljivosti (uključujući kontaktni dermatitis), konjuktivitisa, posebno alergijskog konjuktivitisa, eozinofilnog bronhitisa, alergije na hranu, eozinofilnog gastroenteritisa, upalne bolesti crijeva, ulceroznog kolitisa i Crohnove bolesti, mastocitoze, autoimunih bolesti poput hiper IgE sindroma i sistemmog eritematoznog lupusa, psorijaze, akni, multiple skleroze, odbacivanja alotransplantata, reperfuzijske ozljede, kronične opstruktivne plućne bolesti, reumatoidnog artritisa, psorijaznog artritisa i osteoartritisa.
to 18.4 degrees; or degrees. 
do 18.4 stupnjeva; ili stupnjeva.
and R2 taken together with the carbon atoms to which they are attached form a C5–C8cyclic ring; and m is 1 or 2. 
R, i Ro zajedno s ugljikovim atomima na koje su pričvršćeni oblikuju Cs-Ce ciklički prsten; i m je I ili 2.
Permeability enhancement and local damage are closely related sequelae of the interaction of surfactants with the intestinal wall (Swenson, E. S., Milisen, W. B., Curatolo, W., Pharm. 
Poboljšanje propusnosti i lokalna oštećenja usko su povezane posljedice interakcije surfaktanta sa crijevnom stjenkom (Swenson, E.S., Milisen, W.B., Curatolo, W., Pharm.
Pivot axis 36 (seen in FIG. 1, and perpendicular to the drawing sheet in FIG. 3A) is generally transverse to longitudinal axis 13 of shaft portion 12 and lies in a plane between first and second side surfaces 14 and 16 . 
Os vrtnje 36 (kako se vidi na Slici 1, 1 okomita na ravninu crtanja na Slici 3A) obično je poprečna uzdužnoj osi 13 trupnog dijela 12 1 leži u ravnini između prve i druge ravne površine 14 i 16.
This provides the further advantage that these runner channels can, if desired, be steered independently of each other during injection, so that the process can be controlled and adjusted depending on the course of the process. 
Time je osigurana daljnja prednost da se s tim protočnim kanalima tijekom ubrizgavanja može, po želji, upravljati međusobno neovisno, tako da se proces može kontrolirati i podesiti ovisno o tijeku procesa.
The process according to claim 1, wherein a remaining part of the catalytic composition, which is not sent to the regenerator, is recycled directly to the dehydrogenation section. 
Postupak u skladu s patentnim zahtjevom 16, naznačen time što se preostali dio katalitičke smjese koji se ne šalje u regenerator reciklira izravno u dehidrogenacijski odjeljak.
A mixture of the above-described crude, 3.98 kg of anhydrous ethyl acetate and 0.35 kg of i -propanol is heated slowly at 55-60°C in a 10-L glass vessel fitted with a heating and cooling system. 
Mješavina gore opisanog sirovog produkta; 3,98 kg bezvodnog acetil acetata 1 0,35 kg i /-propanola se sporo zagrijava pri 55-60*C u staklenoj tikvici od 10 1 na koju je postavljen sustav za hlađenje i grijanje .
A door closer for a door, preferably a glass door, which is supportable by a stationary support structure, the door being movable between an open position and a closed position, the door closer comprising: 
HR P20140446 T1 PATENTNI ZAHTJEVI Spojnica za zatvaranje vrata, poželjno staklenih vrata, koju podupire stacionarna potporna struktura, vrata se pomiču između otvorenog položaja i zatvorenog položaja, spojnica za zatvaranje vrata obuhvaća:
The reaction of the compound of Formula II with the compound of Formula XVb may be carried out under Mitsunobu conditions as described in process (e) above, followed by removal of the protecting group under standard conditions. 
Reakcija između spoja prikazanog Formulom II i spoja prikazanog Formulom XVb može se provesti pod Mitsunobu uvjetima opisanim za gore navedeni postupak (e), nakon čega slijedi uklanjanje zaštitne skupine pod standardnim uvjetima.
This method comprises: 1) exposing one or more compounds of interest to one or more of the antibodies described above for a time and under conditions sufficient for the one or more compounds to bind to the antibody or antibodies; 2) identifying those compounds which bind to the antibody or antibodies, the identified compounds to be used in active immunization in a patient predicted to develop Alzheimer's Disease. 
Alzheimerovu bolest koja uključuje korake: a) izlaganja jednog ili više spojeva koji su od interesa antitijelu temeljem bilo kojeg od zahtjeva 1-4, ili 6 kroz vrijeme i pod uvjetima dostatnima da se navedeni jedan ili više spojeva spoje sa navedenim antitijelom temeljem bilo kojeg od zahtjeva 1-4, ili 6; i b) identificiranje onih spojeva koji se vezuju za navedeno antitijelo temeljem bilo kojeg od prethodnih zahtjeva 14, ili 6, a navedeni spojevi su namijenjeni korištenju kod aktivne aimunizacije kod pacijenata za koje se predviđa da će razviti Alzheimerovu bolest.
The reverse osmosis plant according to claim 1, wherein the swash plate or wobble plate is fixed on an end plate. The reverse osmosis plant according to claim 1, wherein the reverse osmosis plant has at least one reverse osmosis membrane module for separating a feed volume flow into a permeate volume flow and a concentrate volume flow and also lines for feed-, permeate- and concentrate volume flow. 
Postrojenje za povratnu osmozu u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što postrojenje za povratnu osmozu ima najmanje jedan membranski modul za povratnu osmozu, namijenjen razdvajanju volumnog protoka punjenja u volumni protok permeata i volumni protok koncentrata, a također i linije za volumni protok punjenja, permeata i koncentrata.
Cutaneous lymphoma Kidney diseases, which coincide with inflammatory, allergic and/or proliferative processes: 
(vi) bolesti bubrega, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
A nucleic acid encoding a light chain variable region and a heavy chain variable region of the antibody or antigen binding fragment thereof of any one of claims 1 to 5; or a light chain and a heavy chain of the antibody or antigen binding fragment thereof of any one of claims 1 to 5. 
Nukleinska kiselina, naznačena time, da ona kodira varijabilno područje lakog lanca i varijabilno područje teškog lanca od protutijela ili njegovog fragmenta koji veže antigen u skladu s bilo kojim od zahtjeva 1 do 6.
Figure 9 depicts serum cholesterol levels in rats following treatment with 42-O-(D-fructosylcarbonyl)rapamycin and rapamycin. 
Slika 9 prikazuje serumske razine kolesterola u štakora nakon tretmana 42-O-(D-fruktozilkarbonil)rapamicinom i rapamicinom.
There was a significant reduction in the severity of atrophic intestinal changes or enteropathy observed after dosing mice with an equivalent dose of the compound of Example 1 versus gemcitabine HCl. 
Opaženo je značajno smanjenje težine atrofičnih promjena na crijevima ili enteropatija nakon doziranja miševima ekvivalentne doze spoja iz Primjera 1 u odnosu na gemcitabin-HCI.
5, 6 and 7, said antibody being further characterized in that: 
5, 6 1 7, rečeno antitijelo ili njegov dvovalentni funkcionalni fragment, dalje naznačeno time da: i)
Priority of the PCT and European Patent Applications is claimed. 
Datum objave prijevoda patentnih zahtjeva: 31.01.2012.
15A, except that the CALU6 cell line (non-small cell lung cancer cell line) was used instead of the HM7 cell line, Antibody A-2 was found to decrease tumor volume, as shown in FIG. 
Anti-Notch1-NRR-protutijelo za uporabu prema zahtjevu 18, naznačeno time, da poremećaj je adenokarcinom crijeva ili adenom, rak pluća ne-malih stanica, rak jajnika ili karcinom dojke.
In addition, the samples containing 1.0 g/L of the stabilising composition were illuminated under the same conditions for 2, 8 and even 24 hrs. 
Dodatno, uzorci koji su sadržavali 1,0 g/L pripravka za stabiliziranje su osvijetljeni pod istim uvjetima 2,8 i čak 24 sata.
An insect resistant corn plant, or parts thereof, or seed thereof or progeny thereof comprising a DNA molecule encoding Cry2Ab and Cry1A.105 in the genome in the cells of said corn plant, parts, seed or progeny thereof, wherein the DNA molecule comprises the following elements: e35S promoter, wheat CAB untranslated leader, rice actin intron, coding sequence for Cry1A.105, wheat HSP17 3' termination and polyadenylation sequence, FMV promoter, hsp70 intron, rubisco small subunit chloroplast targeting peptide coding sequence, Cry2Ab coding sequence, nos 3' termination and polyadenylation signal sequence, wherein positioned on opposite ends of said DNA molecule are a DNA having the nucleotide sequence of SEQ ID NO:1 and a DNA having the nucleotide sequence of SEQ ID NO:2, and wherein said DNA molecule is present in the corn event MON89034 deposited with American Type Culture Collection (ATCC) with Accession No. 
Biljka kukuruza otporna na insekte, ili dijelovi iste, ili sjeme iste, ili potomstvo iste sadrže DNA molekulu koja kodira CryŽ2Ab i Cry1A.105 u genom u stanice navedene biljke kukuruza, dijelove, sjeme ili potomstvo iste, pri čemu DNA molekula sadrži slijedeće elemente: 6355 promotor, CAB neprevođenu začetnicu pšeničnog gena, aktinski intron iz gena riže, Cry1A.105 kodirajuću sekvencu, HPS17 3? terminacijsku i poliadenilacijsku sekvencu pšenice, FMV promotor, hsp70 intron, kodirajuću sekvencu za malu podjedinicu kloroplasnog rubisco ciljnog peptida, Cry2Ab kodirajuću sekvencu, nos 3? terminacijsku i poliadenilacijsku signalnu sekvencu, pri čemu su na suprotne krajeve opisane molekule DNA dodane nukleotidne sekvence SEQ ID NO: 1 i sekvenca SEQ ID NO: 2,1 pri čemu je spomenuta DNA molekula prisutna u kukuruzu oznake MON89034 pohranjenog kod American Type Culture Collection (ATCC) s pristupnim brojem PTA-7455.